As Lipitor Lawsuits Move Forward, Bernstein Liebhard LLP Notes New Study Suggesting an Association Between Type 2 Diabetes and Statin Use

Share Article

The Firm is evaluating potential Lipitor lawsuits on behalf of individuals who developed Type 2 diabetes allegedly due to their use of the statin medication.

Free Case Review
The publication of this study comes as hundreds of plaintiffs in the U.S. pursue Lipitor lawsuits that allege the use of this statin increased their risk for diabetes.

As Lipitor lawsuits (http://www.lipitorlawsuitcenter.com/) that allege use of the statin medication caused patients to develop Type 2 diabetes continue to move forward in U.S. courts, Bernstein Liebhard LLP notes the publication of a new study which suggests that long-term statin use may increase an individual’s risk of developing the disease. According to a report published by The Telegraph, researchers from University College London's Institute of Cardiovascular Science analyzed data from up to 220,000 people and results from almost 130,000 patients who took part in previous statin studies. They concluded that the use of statins was associated with a 12% increased risk of developing type 2 diabetes over a four-year period. *

“The publication of this study comes as hundreds of plaintiffs in the U.S. pursue Lipitor lawsuits that allege the use of this statin increased their risk for diabetes. This is just the latest research to point to a link between the medications and the development of the disease,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free and confidential case reviews to individuals who allegedly developed diabetes due to their use of Lipitor.

Lipitor Diabetes Litigation

According to the U.S. Food & Drug Administration (FDA), statins are a class of prescription drugs used together with diet and exercise to reduce blood levels of LDL, or bad, cholesterol.** In February 2012, the FDA mandated that the labels of Lipitor and other statins be modified to included new information about their association with Type 2 diabetes.*** The agency acted after a study published in JAMA: Internal Medicine reported that post-menopausal women treated with statins were at increased risk of developing the disease.****

In May 2013, the British Medical Journal also reported an association between atorvastatin, the active ingredient in Lipitor, and diabetes, finding that patients who took the drug had a 22 percent increased risk of new-onset diabetes.*****

Court documents indicate that more than 1,200 Lipitor lawsuits have been filed in the federal multidistrict litigation now underway in U.S. District Court, District of South Carolina on behalf of plaintiffs who allege the medication increases the risk for developing Type 2 diabetes. The complaints accuse Pfizer Inc. of being aware of the association between the medication and diabetes, and of concealing this knowledge from doctors and patients. Plaintiffs further maintain that the label changes made by Pfizer in 2012 were inadequate, and still do not sufficiently warn Lipitor users that they may be at increased risk for Type 2 diabetes. (In re Lipitor (Atorvastatin) Litigation, MDL No. 2502)

Individuals who allegedly developed diabetes due to their use of Lipitor may be entitled to compensation for medical bills, lost wages, pain and suffering and other damages. Learn more about filing a Lipitor lawsuit, please visit Bernstein Liebhard LLP’s website, or call 800-511-5092 to obtain a free legal review.

*telegraph.co.uk/health/healthnews/11116875/Statins-increase-weight-and-blood-sugar-and-raise-diabetes-risk-study-finds.html, Telegraph, September 23, 2014
**fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm294358.htm, FDA, November 2012
***fda.gov/forconsumers/consumerupdates/ucm293330.htm, FDA, February 2012
****archinte.jamanetwork.com/article.aspx?articleid=1108676, JAMA Internal Medicine, January 2012
*****bmj.com/content/346/bmj.f2610, BMJ, May 2013

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
http://www.lipitorlawsuitcenter.com/
https://plus.google.com/115936073311125306742?rel=author

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Felecia L. Stern
Follow us on
Visit website